| Recent years, It is realized that dyslipidemia plays an very important role in the generation and development of atherosclerosis (AS) and the cardiovascular events caused by AS. It is admitted that the high levels of total cholesterol and triglyceride are independent risk factor on coronary heart diseas(CHD). The high level of low density lipoprotein-cholesterol(LDL-C)is one of high risk factors which cause CHD as well. While high density lipoprotein-cholesterol(HDL-C) is a good factor on antagonizing AS. The effect of lipid-regulating treatment has been confirmed on one degree and two degree prevention of CHD. Ginkgo Biloba Extract(GBE) and Xue zhikang were extracted from ginkgo biloba L and special HongQu, respectively, which have lipid-regulating function. In this study the pharmacological action of ginkgo biloba extract new prescrintion(GBENP) was investigated on experimental hyperlipidmia and the effect and safe of Xuezikang was observed in the patients with primary hyperlipidmia.60 rats were randomly divided into six groups: normal group, Hyperlipidemic model group, GBENP low, middle and high dose groups, as well as lipanthyl group. Except for the normal group, the other five groups were given fatty emulsion. Among them, three groups were treated with GBENP (20mg/kg.d, 40mg/kg.d,80mg/kg.d, respectively) by ig administration ,and one group was given lipanthyl(25mg/kg.d)by ig administration as the positive drug control, another group was received aqua destillata by ig administration as the hyperlipidemic control. The treatnent were consecutively carried out for 28 days. After the last time of treatment, the coeliac arteria blood of all the rats was taken and the serum lipids levels of each rat were tested. Results: GBENP could significantly decrease the levels of TC and LDL-C (P<0.01), increase the contents of serum HDL-C and apolipoprotein AI(apoAI)(P<0.05), and reduce theconcentration of apolipoprotein B (apoB)(P<0.05) as compared with the hyperlipidemic model group. In middle and high dose groups GBENP could slightly improve the hepatic fatty degeneration in experimental hyperlipidemic rats. Conclusion: GBENP has the preventoin of hyperlipidemic formation in rats induced by feeding fatty emulsion.60 Anchuns were randomly divided into six groups: normal group, hyperlipidemic model group and GBENP low, middle and high dose groups, as well as lipanthyl group. Except for the normal group, the other five groups were firstly given high fat food for two weeks. Then among them, three groups were treated with GBENP(20mg/kg.d, 40mg/kg.d, 80mg/kg.d, respectively) by ig administration, and one group was given lipanthyl(25mg/kg.d)by ig administration as the positve drug, another group was received aqua destillata by ig administration as the hyperlipidemic model. The treatment were consecutively carried out for four weeks. At the end, the vena jugularis externa blood of all the Anchuns was taken and the serum lipid level of each Anchun was tested. Results: GBENP in low dose group could significantly decrease the levels of TC, LDL-C(PO.OOl) and TG(P<0.05), in middle and high does groups, GBENP could remarkably reduce the levels of TC, TG and LDL-C(P<0.001-0.01), at the same time, high does GBENP could rise the level of the apoAI(P<0.05). The drug could reduce the concentration of apoB(P<0.01-0.05) and obviously reduce the ratio of TC-HDL-C/HDL-C in the hyperlipidemic Anchun(P<0.001-0.01) as well. Although GBENP has the tendency of increasing the content of HDL-C, the significant difference was no found. GBENP obviously reduce the coefficient of liver weight (P<0.01-0.05) and the degree of hepatic fatty degeneration. Conclusion: GBENP has effects of preventing and treating experimental hyperlipidemia on Anchun.The efficacy and safety of Xuezhikang were assessed in 30 patients who have taken it in a does of 1.2g daily for 8 weeks. Results: Aftertreated with the drug for 8 weeks, the TC, TG, LDL-C were decreased by 19.4%, 29.8% and 26.3%, respectiuely, while HDL-C was increased by 11.5% and th... |
PDF Full Text Request